(DNA + RNA fusions) Oncomine Comprehensive myeloid/ Leukemia Panel

The Oncomine Comprehensive Myeloid/Leukemia Panel is a groundbreaking test designed to provide in-depth insights into genetic mutations, fusions, and other molecular changes in myeloid leukemia and other hematologic cancers. This advanced diagnostic panel is used to detect a broad range of DNA and RNA fusion events that play a significant role in the pathogenesis of myeloid malignancies, including leukemia. The test is essential for accurate cancer diagnostics, offering precision in the identification of fusion genes that are crucial for personalized treatment planning.

Purpose / Clinical Significance:

• The Oncomine Comprehensive Myeloid/Leukemia Panel is designed for identifying specific DNA and RNA fusions in leukemia and other myeloid disorders. By detecting fusion genes, the panel aids in understanding the molecular basis of disease, supporting the treatment and management of leukemia patients.

• It is especially significant for those who have been diagnosed with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or other hematological malignancies.

• This panel helps oncologists determine the best course of action based on the fusion genes present, making it crucial for targeted therapies and personalized treatment plans.

Principle:

• The Oncomine test utilizes next-generation sequencing (NGS) technology, which offers high-throughput and accurate detection of both DNA and RNA fusion events. By sequencing both the DNA and RNA of the patient's cells, the test captures gene fusions that play a critical role in the development and progression of myeloid leukemia and other hematologic malignancies.

• This panel focuses on analyzing hundreds of genetic alterations associated with leukemia, improving the understanding of the cancer at a molecular level.

Common Methods:

• Next-Generation Sequencing (NGS) is the most common and effective method used in the Oncomine panel. This technology enables simultaneous sequencing of both DNA and RNA, ensuring comprehensive analysis of gene fusions, mutations, and other genetic alterations that may influence treatment options.

• The panel can detect various genetic alterations, including those in oncogenes such as BCR-ABL1, KIT, FLT3, and NPM1, among others, crucial for guiding therapy decisions.

Recommended Usage:

• The Oncomine Comprehensive Myeloid/Leukemia Panel is recommended for use in:

  • Diagnosing and monitoring myeloid leukemia and related hematological disorders.

  • Assessing fusion genes to tailor treatment options for leukemia patients.

  • Supporting genetic counseling for patients and families, helping in decision-making regarding cancer therapies.

  • Identifying predictive biomarkers that are relevant for targeted treatments in both newly diagnosed and relapsed leukemia patients.

Benefits of the Oncomine Comprehensive Myeloid/Leukemia Panel:

1. Enhanced Diagnostic Accuracy: Provides detailed genetic insights that improve the accuracy of diagnosing leukemia and myeloid malignancies.

2. Personalized Treatment Plans: Identifies actionable genetic alterations, enabling oncologists to recommend targeted therapies specific to the patient’s cancer type.

3. Early Detection of Genetic Mutations: The panel's ability to detect rare genetic mutations and fusion genes allows for early intervention, improving patient outcomes.

4. Advanced Technology: Powered by next-generation sequencing (NGS), ensuring precise results in a timely manner, enabling quicker decisions for effective treatment strategies.

5. Comprehensive Testing: Analyzes a wide array of genetic alterations in one comprehensive test, saving time and reducing the need for multiple tests.

Common Side Effects of Oncomine Testing:

• While the Oncomine test itself is non-invasive and poses minimal risk, some mild discomfort might occur from the blood draw (phlebotomy) required for the test.

• There are no known side effects directly associated with the test, but some patients may experience temporary pain or bruising at the site of the blood draw.

Conclusion:
The Oncomine Comprehensive Myeloid/Leukemia Panel is a pivotal tool for precision medicine, providing comprehensive, accurate, and actionable genetic data to improve the diagnosis and treatment of leukemia and myeloid disorders. With the ability to identify critical genetic mutations and fusions, this test empowers healthcare providers in Dubai and worldwide to make informed decisions that can significantly impact patient outcomes.